Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
EMPA-REG OUTCOME Trial: Reducing Cardiovascular Risk For T2D Patients
Letter from the Editor
Last week our intern Marian Ayad, BSPharm, PharmD candidate, University of Colorado, was talking to me about the problems that occur when there is a lower age limit on the use of a medication. She had been reviewing PI’s on various diabetes medications and constantly found that most of them had a minimum age for use.
She was well aware that prescribers can “write off label” but found that they were hesitant when it came to age restrictions.
Usually these age restrictions were in place because the manufacturer had not tested the product in that younger age group, and were not tied to any adverse events.
This week she was able to find a study that looked at the benefits of using liraglutide in a younger population, and the benefits may be enough to make you think about changing your prescribing habits.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES -- Diabetes News and Research
The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
The lack of studies for children and adolescents with type 2 diabetes has led to an absence of approval of new drugs for this patient population. This study reports findings of Liraglutide for youth.
Why having a high bone mineral density may not always decrease the risk of fractures.
Did You Know: Can These Treatments' Results Vary According to Race?
While recent cardiovascular safety trials (CVST) of newer diabetes medications included mostly whites, results are being generalized to all races in recent guidelines. This raises a controversial question regarding the ability to apply CVST data to black patients with type 2 diabetes. In this meta-analysis of trials involving GLP‐1 receptor agonists, SGLT2 inhibitors, and DPP‐4 inhibitors, the authors evaluated the association between major adverse cardiovascular events (MACE) and treatment with these agents in black individuals with type 2 diabetes. Treatment with GLP‐1 receptor agonists, SGLT2 inhibitors, or DPP-4 inhibitors did not produce a significant difference in MACE outcomes compared with placebo in this population. However, the authors did note that many of these trials did not accurately evaluate racial differences in treatment outcomes. Given that black patients with type 2 diabetes were not well represented in CVST and such trials were underpowered to evaluate racial differences, it remains unclear whether GLP‐1RA, SGLT‐2i or DPP-4 inhibitors would reduce cardiovascular risk in such patients, and additional studies targeting black patients are urgently needed. Circulation. 2019;139(18):2098 Diabetes June 12, 2019
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Marian Ayad, BPharm, PharmD candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Emma Kammerer, PharmD Candidate, Class of 2020, L|E|C|O|M Bradenton School of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.